Brief: Medicenna Announces Preclinical Data On Mdna11 At The Cytokine-Based Cancer Immunotherapies Summit
25/03/2021 11:07
March 25 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA ANNOUNCES PRECLINICAL DATA ON MDNA11 WITH
ANTI-PD-1
THERAPY AND UNVEILS NOVEL BIFUNCTIONAL SUPERKINES AT THE
CYTOKINE-BASED CANCER IMMUNOTHERAPIES SUMMIT
* MEDICENNA THERAPEUTICS CORP - MDNA11 AND ANTI-PD-1
COMBINATION
LEADS TO COMPLETE RESPONSES IN A MURINE SOLID TUMOR MODEL
* MEDICENNA THERAPEUTICS CORP - PRECLINICAL DATA
DEMONSTRATES
POTENTIAL OF BISKITS(TM) TO EFFECTIVELY TARGET IMMUNOLOGICALLY
"COLD" TUMORS
Source text for Eikon: ID:nGNX6mdJkh
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results